New targets for type 2-low asthma

키워드

참고문헌 (85)

1. "Pocket guide for asthma management and prevention" (2022)[URL]
2. Cao TBT, "Tissue inhibitor of metalloproteinase-1 enhances eosinophilic airway inflammation in severe asthma", Allergy Asthma Immunol Res, 15, pp.451~472 (2023)
3. Quoc QL, "S100A9 in adult asthmatic patients : a biomarker for neutrophilic asthma", Exp Mol Med, 53, pp.1170~1179 (2021)
4. Bich TCT, "Serum amyloid A1 : a biomarker for neutrophilic airway inflammation in adult asthmatic patients", Allergy Asthma Immunol Res, 14, pp.40~58 (2022)
5. Lee DH, "Epithelial autoantigen-specific IgG antibody enhances eosinophil extracellular trap formation in severe asthma", Allergy Asthma Immunol Res, 14, pp.479~493 (2022)
6. Ricciardolo FLM, "Which therapy for non-type(T)2", T2-low asthma, 2021, pp.12, 10~
7. Moore WC, "Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis", J Allergy Clin Immunol, 133, pp.1557~1563 (2014)
8. Shi B, "Characteristics of inflammatory phenotypes among patients with asthma : relationships of blood count parameters with sputum cellular phenotypes", Allergy Asthma Clin Immunol, 17, pp.47~ (2021)
9. Kyriakopoulos C, "Identification and treatment of T2-low asthma in the era of biologics", ERJ Open Res, 7, pp.00309-2020~ (2021)
10. Shah SP, "Exploring the utility of noninvasive type 2 inflammatory markers for prediction of severe asthma exacerbations in children and adolescents", J Allergy Clin Immunol Pract, 7, pp.2624~2633 (2019)
11. Heaney LG, "Composite type-2biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma : a multicentre, single-blind, parallel group, randomised controlled trial", Lancet Respir Med, 9, pp.57~68 (2021)
12. Carr TF, "Treatment approaches for the patient with T2 low asthma", Ann Allergy Asthma Immunol, 127, pp.530~535 (2021)
13. Wen Y, "Assessment of airway inflammation using sputum, BAL, and endobronchial biopsies in current and ex-smokers with established COPD", Int J Chron Obstruct Pulmon Dis, 5, pp.327~334 (2010)
14. Agache I, "Monitoring inflammatory heterogeneity with multiple biomarkers for multidimensional endotyping of asthma", J Allergy Clin Immunol, 141, pp.442~445 (2018)
15. Schleich FN, "Distribution of sputum cellular phenotype in a large asthma cohort : predicting factors for eosinophilic vs neutrophilic inflammation", BMC Pulm Med, 13, pp.11~ (2013)
16. Spanevello A, "Induced sputum cellularity. Reference values and distribution in normal volunteers", Am J Respir Crit Care Med, 162(3 Pt 1), pp.1172~1174 (2000)
17. Simpson JL, "Inflammatory subtypes in asthma : assessment and identification using induced sputum", Respirology, 11, pp.54~61 (2006)
18. Belda J, "Induced sputum cell counts in healthy adults", Am J Respir Crit Care Med, 161(2 Pt 1), pp.475~478 (2000)
19. Hur GY, "Serum potential biomarkers according to sputum inflammatory cell profiles in adult asthmatics", Korean J Intern Med, 35, pp.988~997 (2020)
20. Ntontsi P, "Clinical, functional and inflammatory characteristics in patients with paucigranulocytic stable asthma : comparison with different sputum phenotypes", Allergy, 72, pp.1761~1767 (2017)
21. Bullone M, "Elevated serum IgE, oral corticosteroid dependence and IL-17", 22 expression in highly neutrophilic asthma, 2019, pp.54, 1900068~
22. Chupp GL, "A chitinase-like protein in the lung and circulation of patients with severe asthma", N Engl J Med, 357, pp.2016~2027 (2007)
23. Hinks TSC, "Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1", J Allergy Clin Immunol, 138, pp.61~75 (2016)
24. Gibson PG, "Heterogeneity of airway inflammation in persistent asthma : evidence of neutrophilic inflammation and increased sputum interleukin-8", Chest, 119, pp.1329~1336 (2001)
25. Kuipers I, "Increased glutaredoxin-1and decreased protein S-glutathionylation in sputum of asthmatics", Eur Respir J, 41, pp.469~472 (2013)
26. Hastie AT, "Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes", J Allergy Clin Immunol, 125, pp.1028~1036 (2010)
27. Tliba O, "Paucigranulocytic asthma : uncoupling of airway obstruction from inflammation", J Allergy Clin Immunol, 143, pp.1287~1294 (2019)
28. Diver S, "Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma(CASCADE) : a double-blind, randomised, placebo-controlled, phase 2 trial", Lancet Respir Med, 9, pp.1299~1312 (2021)
29. Wechsler ME, "Efficacy and safety of itepekimab in patients with moderate-to-severe asthma", N Engl J Med, 385, pp.1656~1668 (2021)
30. Kelsen SG, "Astegolimab(anti-ST2)efficacy and safety in adults with severe asthma : A randomized clinical trial", J Allergy Clin Immunol, 148, pp.790~798 (2021)
31. Crim C, "IL-33 receptor inhibition in subjects with uncontrolled asthma : a randomized, placebo-controlled trial", J Allergy Clin Immunol Glob, 1, pp.198~208 (2022)
32. Watz H, "Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma", Pulm Pharmacol Ther, 45, pp.121~123 (2017)
33. O’Byrne PM, "Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma : a randomised, double-blind, placebo-controlled trial", Lancet Respir Med, 4, pp.797~806 (2016)
34. Djukanović R, "The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. a randomized trial", Am J Respir Crit Care Med, 190, pp.145~154 (2014)
35. McCrae C, "INEXAS : a phase 2randomized trial of on-demand inhaled interferon beta-1a in severe asthmatics", Clin Exp Allergy, 51, pp.273~283 (2021)
36. Busse WW, "Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma", Am J Respir Crit Care Med, 188, pp.1294~1302 (2013)
37. "Study to assess the efficacy and safety of CJM112 in patients with inadequately controlled severe asthma" (2017)[URL]
38. Brightling CE, "Risankizumab in severe asthma-a phase 2a, placebo-controlled trial", N Engl J Med, 385, pp.1669~1679 (2021)
39. Hernandez ML, "IL-1 receptor antagonist reduces endotoxin-induced airway inflammation in healthy volunteers", J Allergy Clin Immunol, 135, pp.379~385 (2015)
40. Kardas G, "Monoclonal antibodies in the management of asthma : Dead ends, current status and future perspectives", Front Immunol, 13, pp.983852~ (2022)
41. "A phase 2a study to evaluate the effects of sirukumab in subjects with severe poorly controlled asthma" (2016)[URL]
42. "PrecISE (precision interventions for severe and/or exacerbation-prone asthma) network study" (2019)[URL]
43. Berry MA, "Evidence of a role of tumor necrosis factor alpha in refractory asthma", N Engl J Med, 354, pp.697~708 (2006)
44. Wenzel SE, "A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma", Am J Respir Crit Care Med, 179, pp.549~558 (2009)
45. Huang CY, "Recent progress in TGF-β inhibitors for cancer therapy", Biomed Pharmacother, 134, pp.111046~ (2021)
46. Sartiani L, "Pharmacological basis of the antifibrotic effects of pirfenidone : Mechanistic insights from cardiac in-vitro and in-vivo models", Front Cardiovasc Med, 9, pp.751499~ (2022)
47. Jin R, "IL-33-induced neutrophil extracellular traps degrade fibronectin in a murine model of bronchopulmonary dysplasia", Cell Death Discov, 6, pp.33~ (2020)
48. Pelaia C, "Tezepelumab : a potential new biological therapy for severe refractory asthma", Int J Mol Sci, 22, pp.4369~ (2021)
49. Pham DL, "Neutrophil autophagy and extracellular DNA traps contribute to airway inflammation in severe asthma", Clin Exp Allergy, 47, pp.57~70 (2017)
50. Quoc QL, "Contribution of monocyte and macrophage extracellular traps to neutrophilic airway inflammation in severe asthma", Allergol Int, 73, pp.81~93 (2024)
51. Badi YE, "IL1RAP expression and the enrichment of IL-33 activation signatures in severe neutrophilic asthma", Allergy, 78, pp.156~167 (2023)
52. Chung KF, "Asthma phenotyping : a necessity for improved therapeutic precision and new targeted therapies", J Intern Med, 279, pp.192~204 (2016)
53. Rahmawati SF, "Pharmacological rationale for targeting IL-17 in asthma", Front Allergy, 2, pp.694514~ (2021)
54. Li SF, "Type I interferons : distinct biological activities and current applications for viral infection", Cell Physiol Biochem, 51, pp.2377~2396 (2018)
55. Bhakta NR, "IFN-stimulated gene expression, type 2 inflammation, and endoplasmic reticulum stress in asthma", Am J Respir Crit Care Med, 197, pp.313~324 (2018)
56. Annunziato F, "The 3 major types of innate and adaptive cell-mediated effector immunity", J Allergy Clin Immunol, 135, pp.626~635 (2015)
57. Kim J, "Innate immune crosstalk in asthmatic airways : Innate lymphoid cells coordinate polarization of lung macrophages", J Allergy Clin Immunol, 143, pp.1769~1782 (2019)
58. Raundhal M, "High IFN-γ and low SLPI mark severe asthma in mice and humans", J Clin Invest, 125, pp.3037~3050 (2015)
59. Gauthier M, "Severe asthma in humans and mouse model suggests a CXCL10 signature underlies corticosteroid-resistant Th1 bias", JCI Insight, 2, pp.e94580~ (2017)
60. Singhania A, "Multitissue transcriptomics delineates the diversity of airway T cell functions in asthma", Am J Respir Cell Mol Biol, 58, pp.261~270 (2018)
61. Östling J, "IL-17-high asthma with features of a psoriasis immunophenotype", J Allergy Clin Immunol, 144, pp.1198~1213 (2019)
62. Krishnamoorthy N, "Neutrophil cytoplasts induce TH17 differentiation and skew inflammation toward neutrophilia in severe asthma", Sci Immunol, 3, pp.eaao4747~ (2018)
63. Pelletier M, "Evidence for a crosstalk between human neutrophils and Th17 cells", Blood, 115, pp.335~343 (2010)
64. "Efficacy and safety of BI 655066/ABBV-066(Risankizumab) in patients with severe persistent asthma" (2015)[URL]
65. Hinks TSC, "Treatment options in type-2 low asthma", Eur Respir J, 57, pp.2000528~ (2021)
66. Fricker M, "An altered sputum macrophage transcriptome contributes to the neutrophilic asthma endotype", Allergy, 77, pp.1204~1215 (2022)
67. van der Veen TA, "The different faces of the macrophage in asthma", Curr Opin Pulm Med, 26, pp.62~68 (2020)
68. Kim RY, "Role for NLRP3 inflammasome-mediated, IL-1β-dependent responses in severe, steroid-resistant asthma", Am J Respir Crit Care Med, 196, pp.283~297 (2017)
69. Lachowicz-Scroggins ME, "Extracellular DNA, neutrophil extracellular traps, and inflammasome activation in severe asthma", Am J Respir Crit Care Med, 199, pp.1076~1085 (2019)
70. Choi Y, "Extracellular vesicles, a key mediator to link environmental microbiota to airway immunity", Allergy Asthma Immunol Res, 9, pp.101~106 (2017)
71. Choi Y, "Which factors associated with activated eosinophils contribute to the pathogenesis of aspirin-exacerbated respiratory disease?", Allergy Asthma Immunol Res, 11, pp.320~329 (2019)
72. Choi Y, "Distinct functions of eosinophils in severe asthma with type 2 phenotype : clinical implications", Korean J Intern Med, 35, pp.823~833 (2020)
73. Choi Y, "Urine microbial extracellular vesicles can be potential and novel biomarkers for allergic diseases", Allergy Asthma Immunol Res, 13, pp.5~7 (2021)
74. Lee DH, "Immunoregulatory effects of Lactococcus lactis-derived extracellular vesicles in allergic asthma", Clin Transl Allergy, 12, pp.e12138~ (2022)
75. Choi Y, "Bacterial extracellular vesicles : a candidate molecule for the diagnosis and treatment of allergic diseases", Allergy Asthma Immunol Res, 15, pp.279~289 (2023)
76. Sim S, "Micrococcus luteus-derived extracellular vesicles attenuate neutrophilic asthma by regulating miRNAs in airway epithelial cells", Exp Mol Med, 55, pp.196~204 (2023)
77. Yokoyama A, "Circulating interleukin-6 levels in patients with bronchial asthma", Am J Respir Crit Care Med, 151, pp.1354~1358 (1995)
78. Chu DK, "Therapeutic potential of anti-IL-6 therapies for granulocytic airway inflammation in asthma", Allergy Asthma Clin Immunol, 11, pp.14~ (2015)
79. Peters MC, "Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity : a cross-sectional analysis of two cohorts", Lancet Respir Med, 4, pp.574~584 (2016)
80. Gubernatorova EO, "Novel anti-cytokine strategies for prevention and treatment of respiratory allergic diseases", Front Immunol, 12, pp.601842~ (2021)
81. Peters MC, "A transcriptomic method to determine airway immune dysfunction in T2-high and T2-low asthma", Am J Respir Crit Care Med, 199, pp.465~477 (2019)
82. Avci AB, "Targeting IL-6 or IL-6 receptor in rheumatoid arthritis : what’s the difference?", BioDrugs, 32, pp.531~546 (2018)
83. Thomas PS, "Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects", Am J Respir Crit Care Med, 152, pp.76~80 (1995)
84. Kramer EL, "Early growth response-1 suppresses epidermal growth factor receptor-mediated airway hyperresponsiveness and lung remodeling in mice", Am J Respir Cell Mol Biol, 41, pp.415~425 (2009)
85. Halwani R, "Role of transforming growth factor-β in airway remodeling in asthma", Am J Respir Cell Mol Biol, 44, pp.127~133 (2011)

관련 논문AI추천